Literature DB >> 15543491

Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations.

F Bergametti1, C Denier, P Labauge, M Arnoult, S Boetto, M Clanet, P Coubes, B Echenne, R Ibrahim, B Irthum, G Jacquet, M Lonjon, J J Moreau, J P Neau, F Parker, M Tremoulet, E Tournier-Lasserve.   

Abstract

Cerebral cavernous malformations (CCMs) are hamartomatous vascular malformations characterized by abnormally enlarged capillary cavities without intervening brain parenchyma. They cause seizures and cerebral hemorrhages, which can result in focal neurological deficits. Three CCM loci have been mapped, and loss-of-function mutations were identified in the KRIT1 (CCM1) and MGC4607 (CCM2) genes. We report herein the identification of PDCD10 (programmed cell death 10) as the CCM3 gene. The CCM3 locus has been previously mapped to 3q26-27 within a 22-cM interval that is bracketed by D3S1763 and D3S1262. We hypothesized that genomic deletions might occur at the CCM3 locus, as reported previously to occur at the CCM2 locus. Through high-density microsatellite genotyping of 20 families, we identified, in one family, null alleles that resulted from a deletion within a 4-Mb interval flanked by markers D3S3668 and D3S1614. This de novo deletion encompassed D3S1763, which strongly suggests that the CCM3 gene lies within a 970-kb region bracketed by D3S1763 and D3S1614. Six additional distinct deleterious mutations within PDCD10, one of the five known genes mapped within this interval, were identified in seven families. Three of these mutations were nonsense mutations, and two led to an aberrant splicing of exon 9, with a frameshift and a longer open reading frame within exon 10. The last of the six mutations led to an aberrant splicing of exon 5, without frameshift. Three of these mutations occurred de novo. All of them cosegregated with the disease in the families and were not observed in 200 control chromosomes. PDCD10, also called "TFAR15," had been initially identified through a screening for genes differentially expressed during the induction of apoptosis in the TF-1 premyeloid cell line. It is highly conserved in both vertebrates and invertebrates. Its implication in cerebral cavernous malformations strongly suggests that it is a new player in vascular morphogenesis and/or remodeling.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15543491      PMCID: PMC1196432          DOI: 10.1086/426952

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  24 in total

1.  Mutations in the gene encoding KRIT1, a Krev-1/rap1a binding protein, cause cerebral cavernous malformations (CCM1).

Authors:  T Sahoo; E W Johnson; J W Thomas; P M Kuehl; T L Jones; C G Dokken; J W Touchman; C J Gallione; S Q Lee-Lin; B Kosofsky; J H Kurth; D N Louis; G Mettler; L Morrison; A Gil-Nagel; S S Rich; J M Zabramski; M S Boguski; E D Green; D A Marchuk
Journal:  Hum Mol Genet       Date:  1999-11       Impact factor: 6.150

Review 2.  [131 cases of cavernous angioma (cavernomas) of the CNS, discovered by retrospective analysis of 24,535 autopsies].

Authors:  P Otten; G P Pizzolato; B Rilliet; J Berney
Journal:  Neurochirurgie       Date:  1989       Impact factor: 1.553

3.  Cerebral cavernous malformations. Incidence and familial occurrence.

Authors:  D Rigamonti; M N Hadley; B P Drayer; P C Johnson; K Hoenig-Rigamonti; J T Knight; R F Spetzler
Journal:  N Engl J Med       Date:  1988-08-11       Impact factor: 91.245

4.  cDNA cloning and expression of an apoptosis-related gene, humanTFAR15 gene.

Authors:  Y Wang; H Liu; Y Zhang; D Ma
Journal:  Sci China C Life Sci       Date:  1999-06

5.  Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus.

Authors:  D Viskochil; A M Buchberg; G Xu; R M Cawthon; J Stevens; R K Wolff; M Culver; J C Carey; N G Copeland; N A Jenkins
Journal:  Cell       Date:  1990-07-13       Impact factor: 41.582

6.  Association of Krev-1/rap1a with Krit1, a novel ankyrin repeat-containing protein encoded by a gene mapping to 7q21-22.

Authors:  I Serebriiskii; J Estojak; G Sonoda; J R Testa; E A Golemis
Journal:  Oncogene       Date:  1997-08-28       Impact factor: 9.867

7.  Identification and characterization of the tuberous sclerosis gene on chromosome 16.

Authors: 
Journal:  Cell       Date:  1993-12-31       Impact factor: 41.582

8.  Mutations within the MGC4607 gene cause cerebral cavernous malformations.

Authors:  C Denier; S Goutagny; P Labauge; V Krivosic; M Arnoult; A Cousin; A L Benabid; J Comoy; P Frerebeau; B Gilbert; J P Houtteville; M Jan; F Lapierre; H Loiseau; P Menei; P Mercier; J J Moreau; A Nivelon-Chevallier; F Parker; A M Redondo; J M Scarabin; M Tremoulet; M Zerah; J Maciazek; E Tournier-Lasserve
Journal:  Am J Hum Genet       Date:  2004-01-22       Impact factor: 11.025

9.  Multilocus linkage identifies two new loci for a mendelian form of stroke, cerebral cavernous malformation, at 7p15-13 and 3q25.2-27.

Authors:  H D Craig; M Günel; O Cepeda; E W Johnson; L Ptacek; G K Steinberg; C S Ogilvy; M J Berg; S C Crawford; R M Scott; E Steichen-Gersdorf; R Sabroe; C T Kennedy; G Mettler; M J Beis; A Fryer; I A Awad; R P Lifton
Journal:  Hum Mol Genet       Date:  1998-11       Impact factor: 6.150

10.  KRIT1/cerebral cavernous malformation 1 protein localizes to vascular endothelium, astrocytes, and pyramidal cells of the adult human cerebral cortex.

Authors:  Ozlem Guzeloglu-Kayisli; Nduka M Amankulor; Jennifer Voorhees; Guven Luleci; Richard P Lifton; Murat Gunel
Journal:  Neurosurgery       Date:  2004-04       Impact factor: 4.654

View more
  165 in total

1.  Molecular recognition of leucine-aspartate repeat (LD) motifs by the focal adhesion targeting homology domain of cerebral cavernous malformation 3 (CCM3).

Authors:  Xiaofeng Li; Weidong Ji; Rong Zhang; Ewa Folta-Stogniew; Wang Min; Titus J Boggon
Journal:  J Biol Chem       Date:  2011-06-01       Impact factor: 5.157

2.  Phosphorylation sites in the cerebral cavernous malformations complex.

Authors:  Jaehong Kim; Nicholas E Sherman; Jay W Fox; Mark H Ginsberg
Journal:  J Cell Sci       Date:  2011-12-01       Impact factor: 5.285

Review 3.  Pathogenesis of vascular anomalies.

Authors:  Laurence M Boon; Fanny Ballieux; Miikka Vikkula
Journal:  Clin Plast Surg       Date:  2011-01       Impact factor: 2.017

Review 4.  STRIPAK complexes in cell signaling and cancer.

Authors:  Z Shi; S Jiao; Z Zhou
Journal:  Oncogene       Date:  2016-02-15       Impact factor: 9.867

5.  Systems biology and proteomic analysis of cerebral cavernous malformation.

Authors:  Alexander R Edelmann; Sarah Schwartz-Baxter; Christopher F Dibble; Warren C Byrd; Jim Carlson; Ivandario Saldarriaga; Sompop Bencharit
Journal:  Expert Rev Proteomics       Date:  2014-03-31       Impact factor: 3.940

Review 6.  Endogenous endothelial cell signaling systems maintain vascular stability.

Authors:  Nyall R London; Kevin J Whitehead; Dean Y Li
Journal:  Angiogenesis       Date:  2009-01-27       Impact factor: 9.596

Review 7.  Signaling pathways and the cerebral cavernous malformations proteins: lessons from structural biology.

Authors:  Oriana S Fisher; Titus J Boggon
Journal:  Cell Mol Life Sci       Date:  2013-11-29       Impact factor: 9.261

8.  pak2a mutations cause cerebral hemorrhage in redhead zebrafish.

Authors:  David A Buchner; Fengyun Su; Jennifer S Yamaoka; Makoto Kamei; Jordan A Shavit; Linda K Barthel; Beth McGee; Julio D Amigo; Seongcheol Kim; Andrew W Hanosh; Pudur Jagadeeswaran; Daniel Goldman; Nathan D Lawson; Pamela A Raymond; Brant M Weinstein; David Ginsburg; Susan E Lyons
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-22       Impact factor: 11.205

9.  ccm2-like is required for cardiovascular development as a novel component of the Heg-CCM pathway.

Authors:  Jonathan N Rosen; Vanessa M Sogah; Lillian Y Ye; John D Mably
Journal:  Dev Biol       Date:  2013-01-15       Impact factor: 3.582

10.  Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation.

Authors:  Christopher C Gibson; Weiquan Zhu; Chadwick T Davis; Jay A Bowman-Kirigin; Aubrey C Chan; Jing Ling; Ashley E Walker; Luca Goitre; Simona Delle Monache; Saverio Francesco Retta; Yan-Ting E Shiu; Allie H Grossmann; Kirk R Thomas; Anthony J Donato; Lisa A Lesniewski; Kevin J Whitehead; Dean Y Li
Journal:  Circulation       Date:  2014-12-08       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.